Gapping up
In reaction to earnings/guidance:
- KRNT +16.1%, CSV +9.6%, LOW +6.1%, RDY +5.5%, ADI +4.4%, FRO +4.2%, QIWI +3.7%, VER +2.6%, TGT +0.8%
Other news:
- SURF +30.1% (entered into a clinical trial collaboration with Merck to evaluate the safety and efficacy of combining its SRF617 w/ Keytruda; co also announced ~$30 mln at-the market facility)
- ALDX +26.3% (announced the planned advancement of the investigational new HSP90 inhibitor ADX-1612 to clinical testing for COVID-19)
- INO +23.1% (publication of the preclinical study data for IN0-4800, its COVID-19 DNA vaccine, demonstrating robust neutralizing antibody and T cell immune responses against coronavirus SARS-CoV-2)
- PAE +13.2% (wins 10-year contract to provide aircraft maintenance to US Customs and Border Protection Agency)
- ARR +8.5% (announces resumption of monthly dividends)
- EIGR +8.2% (announces FDA acceptance of NDA for filing with priority review for Zokinvy)
- MYGN +5.6% (FDA approved the BRACAnalysis CDx test for use as a companion diagnostic to identify men with metastatic castration-resistant prostate cancer who are eligible for treatment with Lynparza)
- MODN +3.7% (prices offering of $150.0 mln of convertible senior notes due 2025)
- HAL +3.1% (lowers Q2 dividend of $0.045 a share, prior $0.18 per share)
- NAT +2.9% (to declare Q2 dividend of $0.20 per share, prior $0.14 per share)
- KWR +1.3% (files for 23,000 share common stock offering by selling shareholder)
- LMT +1.2% (to slow pace of production of F-35 jets, according to Reuters; adjusts workforce schedules)
- MRK +0.9% (LYNPARZA (olaparib) was approved by FDA)
Analyst comments:
- CODX +5% (upgraded to Buy from Hold at Maxim Group)
- LNG +4.3% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- CREE +2.8% (upgraded to Neutral from Underweight at JP Morgan)
- FMS +2.7% (upgraded to Equal-Weight from Underweight at Morgan Stanley)
- JPM +1.9% (upgraded to Buy from Hold at Odeon)
- LOGI +1.7% (upgraded to Neutral from Sell at UBS)
- CSX +1.5% (upgraded to Buy from Neutral at UBS)
- BUD +1.2% (upgraded to Neutral from Underweight at JP Morgan)